ImmunityBio announces positive phase II data for Anktiva + checkpoint inhibitors in lung cancer, opens phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ImmunityBio Inc. announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer being treated with checkpoint inhibitors. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Two years ago, Dan Theodorescu made a discovery that could alter biology textbooks: The Y chromosome, widely considered to be a “functional wasteland,” has functions beyond sex determination—and in fact plays a role in cancer biology. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login